Xin Tiandi Receives a Warning Letter from the CSRC for Violations Including Failure to Disclose Major Company Events in a Timely Manner

NightAirdropper · 2026-03-17T17:12:19+00:00

Xintiandi Pharmaceuticals received a warning letter from the China Securities Regulatory Commission (CSRC) for failing to timely disclose material events. The company's idle raised funds management, which was authorized by the board of directors, failed to be redeemed on schedule and was not disclosed. This violation will be recorded in the company's integrity file.

NightAirdropper

2026-03-17 17:12:19

Abstract generation in progress

Securities Star News, on March 16, Xin Tian Di publicly disclosed that Xin Tian Di Pharmaceutical Co., Ltd., Chairman Xie Jianzhong, General Manager Zhang Luyu, Board Secretary Xie Yushan, and Chief Financial Officer Wang Qingkui failed to promptly disclose major company events, allegedly violating securities laws and regulations. They also failed to perform other duties as required, resulting in the China Securities Regulatory Commission Henan Bureau issuing a warning letter.

Detailed violations are as follows:

After investigation, Xin Tian Di Pharmaceutical Co., Ltd. (hereinafter referred to as the company) used idle raised funds for cash management, with the board of directors’ authorization valid until November 30, 2025. After the authorization expired, some of the company’s cash management financial products were not redeemed, and continued to purchase financial products without board approval and without disclosure.

The penalty decision is as follows:

An administrative supervision measure has been taken by issuing a warning letter, and this will be recorded in the securities and futures market integrity archive.

The above content is compiled from public information by Securities Star, generated by AI algorithm (Network Information Backup No. 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.